Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan.
Physiol Res. 2022 Apr 30;71(2):209-217. doi: 10.33549/physiolres.934784. Epub 2022 Mar 28.
Diabetic nephropathy, included in diabetic kidney disease (DKD), is the primary disease leading to end-stage renal disease (ESRD) or dialysis treatment, accounting for more than 40% of all patients with ESRD or receiving dialysis. Developing new therapeutics to prevent the transition to ESRD or dialysis treatment requires an understanding of the pathophysiology of DKD and an appropriate animal model for drug efficacy studies. In this study, we investigated the pathophysiology of diabetic kidney disease with type 2 diabetes in uninephrectomized db/db mice. In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan. The blood and urinary biochemical parameters, main pharmacological endpoint of the losartan therapy, were periodically measured. And at the end, histopathological analysis was performed. Uninephrectomized db/db mice clearly developed obesity and hyperglycemia from young age. Furthermore, they showed renal pathophysiological changes, such as increased urinary albumin-creatinine ratio (UACR) (the peak value 3104 ± 986 in 40-week-old mice), glomerular hypertrophy and increased fibrotic areas in the tubulointerstitial tubules. The blood pressure in the losartan group was significantly low compared to the normotensive Vehicle group. However, as expected, Losartan suppressed the increase in UACR (829±500) indicating the medication was sufficient, but the histopathological abnormalities including tubular interstitial fibrosis did not improve. These results suggest that the uninephrectomized db/db mice are useful as an animal model of the severe DKD indicated by the comparison of the efficacy of losartan in this model with the efficacy of losartan in clinical practice.
糖尿病肾病,包括在糖尿病肾病(DKD),是主要的疾病导致终末期肾病(ESRD)或透析治疗,占所有患者的超过 40%与 ESRD 或接受透析。开发新的治疗方法来预防过渡到 ESRD 或透析治疗需要了解 DKD 的病理生理学和适当的动物模型的药物疗效研究。在这项研究中,我们研究了糖尿病肾病的病理生理学与 2 型糖尿病在单侧肾切除的 db/db 小鼠。此外,肾切除的 db/db 小鼠从 10 周至 42 周,用于评估长期给予血管紧张素Ⅱ受体拮抗剂氯沙坦的疗效。血液和尿液生化参数,氯沙坦治疗的主要药理终点,定期测量。在最后,进行了组织病理学分析。单侧肾切除的 db/db 小鼠清楚地从年轻的时候发展肥胖和高血糖。此外,他们表现出肾脏的病理生理变化,如增加尿白蛋白/肌酐比(UACR)(在 40 周龄小鼠的峰值 3104±986),肾小球肥大和肾小管间质管的纤维化面积增加。氯沙坦组的血压明显低于正常血压的车辆组。然而,正如预期的那样,氯沙坦抑制 UACR 的增加(829±500)表明药物是足够的,但包括肾小管间质纤维化在内的组织病理学异常并没有改善。这些结果表明,单侧肾切除的 db/db 小鼠是有用的作为动物模型的严重 DKD 由比较氯沙坦的疗效在这个模型与氯沙坦的疗效在临床实践。